康哲药业(00867.HK)签订治疗自身免疫性疾病产品许可协议
康哲药业(00867.HK)公布,与medac就於欧洲和美国上市的标准治疗产品签订经销、供应及许可协议。据此,公司获得在中国、香港、澳门及台湾使用由medac拥有或控制的所有相关知识产权和知识产权权利开发、注册及商业化产品的独家许可权利。
产品包括类风湿关节炎和其他自身免疫性疾病的一线替代疗法—甲氨蝶呤预充式注射器/注射笔,以及非肌层浸润性膀胱癌的金标准免疫疗法—膀胱灌注用卡介苗,针对的疾病均於区域存在未被满足的临床需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.